AbbVie Inc (ABBV)vsJanux Therapeutics Inc (JANX)
ABBV
AbbVie Inc
$262.82
+1.11%
HEALTHCARE · Cap: $454.36B
JANX
Janux Therapeutics Inc
$16.93
-0.18%
HEALTHCARE · Cap: $1.01B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 268175% more annual revenue ($64.39B vs $24.00M). ABBV leads profitability with a 9.8% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
JANX
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.0%
Fair Value
$152.16
Current Price
$262.82
$110.66 premium
Margin of Safety
+88.7%
Fair Value
$116.25
Current Price
$16.93
$99.32 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Revenue surging 2178.0% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : JANX
The strongest argument for JANX centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 2178.0% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : JANX
The primary concerns for JANX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ABBV profiles as a value stock while JANX is a hypergrowth play — different risk/reward profiles.
JANX carries more volatility with a beta of 2.52 — expect wider price swings.
JANX is growing revenue faster at 2178.0% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 38/100) and 10.2% revenue growth. JANX offers better value entry with a 88.7% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Janux Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapies based on the patented Tumor Activated T Cell Engager (TRACTr) platform technology to treat cancer patients. The company is headquartered in La Jolla, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?